We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Optical Coherence Tomography Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease (OCTAXUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00704145
Recruitment Status : Completed
First Posted : June 24, 2008
Last Update Posted : February 9, 2010
Information provided by:

Study Description
Brief Summary:
A prospective Optical Coherence Tomography (OCT) study on the completeness of strut coverage and vessel wall response, at different time points (3-6-9 Months), following TAXUS Liberte stent implantation (staged procedures) in patients with multi vessel native coronary artery lesions

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Device: Taxus Libertè™ paclitaxel drug-eluting stent Phase 4

Detailed Description:
Major concerns were addressed to the delayed healing process of drug-eluting stents in off-label indications. To date no studies have detailed the in-vivo completeness of DES coverage at different time points. The objective of this prospective study is to measure the completeness of strut coverage and vessel wall response (neointima disomogeneity, acquired late incomplete strut apposition) at different time points following paclitaxel-eluting stent implantation, in patients with multivessel disease treated with staged PCI procedures. Optical Coherence Tomography (OCT) that detects smaller degrees of stent strut coverage more accurately than IVUS will be used at different time point. Intravascular ultrasound (IVUS) will be performed as per normal practice at any index procedures and 9 months elective follow-up.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Optical Coherence Tomography Study on Completeness of Strut Coverage and Vessel Wall Response at 3-6 and 9 Months Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease
Study Start Date : November 2007
Primary Completion Date : August 2009
Study Completion Date : November 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Paclitaxel
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: A
Device, paclitaxel drug-eluting stent
Device: Taxus Libertè™ paclitaxel drug-eluting stent
device:Taxus Libertè™ (Boston Scientific,Natick,MS)assessed at different time points after implant
Other Name: Taxus Libertè™ (Boston Scientific,Natick,MS)

Outcome Measures

Primary Outcome Measures :
  1. Proportion of uncovered and/or malapposed Taxus Libertè struts at different time point after the implant, as measured by OCT [ Time Frame: 3-6-9 months ]

Secondary Outcome Measures :
  1. % Incomplete apposition at different point of FU (3-6-9 months) [ Time Frame: 3-6-9 months ]
  2. Proportion of neointima disomogeneity around struts at different point of FU (3-6-9 months) [ Time Frame: 3-6-9 months ]
  3. OCT Neointima thickness overtime [ Time Frame: 3-6-9 months ]
  4. Ischemia Driven Target Vessel Failure (ID-TVF) rate at 12 months [ Time Frame: 12 months ]
  5. Adjudicated MACE rate at 30 days and 12 months [ Time Frame: 30 days and 12 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Multivessel coronary artery disease (two or 3 VD) to be treated at 2 sequences (staged procedures) with paclitaxel-polymer eluting stents
  2. Native coronary artery disease with >= 75% diameter stenosis
  3. Vessel size in between 2.5 and 3.5 mm.
  4. Written informed consent signed

Exclusion Criteria:

  1. No suitable anatomy for OCT scan: (truly ostial , tortuous anatomy, very distal lesions or vessels larger than 3.75 in reference diameter).
  2. significant left main coronary artery disease,
  3. lesions in bypass grafts,
  4. acute myocardial infarction,
  5. poor cardiac function as defined by left ventricular ejection fraction ≤ 30%.
  6. allergy to aspirin and or clopidogrel/ticlopidine,
  7. Renal failure with creatinine value > 2.5 mg/dl
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00704145

Ospedali Riuniti di Bergamo
Bergamo, Italy, 24100
Sponsors and Collaborators
A.O. Ospedale Papa Giovanni XXIII
Case Western Reserve University
Boston Scientific Corporation
Principal Investigator: Giulio Guagliumi, MD Cardiovascular Department Ospedali Riuniti di Bergamo
More Information


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Giulio Guagliumi, Ospedali Riuniti di Bergamo
ClinicalTrials.gov Identifier: NCT00704145     History of Changes
Other Study ID Numbers: 1087/2007
First Posted: June 24, 2008    Key Record Dates
Last Update Posted: February 9, 2010
Last Verified: February 2010

Keywords provided by A.O. Ospedale Papa Giovanni XXIII:
Drug Eluting Stents
Percutaneous Coronary Interventions
Optical Coherence Tomography

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action